Details for Patent: 9,233,117

Which drugs does patent 9,233,117 protect, and when does it expire?

Patent 9,233,117 protects SOOLANTRA and is included in one NDA.

This patent has forty-five patent family members in sixteen countries.

Summary for Patent: 9,233,117

Title:	Treatment of inflammatory lesions of rosacea with ivermectin
Abstract:	Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.
Inventor(s):	Jacovella; Jean (Antibes, FR), Chappuis; Jean-Paul (Valbonne, FR), Sordello Wagner; Nathalie (Pegomas, FR), Graeber; Michael (Lawrenceville, NJ), Kaoukhov; Alexandre (Newport Beach, CA), Salin; Laurence (La Roquette sur Siagne, FR), Poncet; Michel (Mougins, FR), Briantais; Philippe (Antibes, FR), Benkali; Khaled (Antibes, FR)
Assignee:	Galderma S. A. (Cham, CH)
Application Number:	14/209,927
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,233,117
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 9,233,117

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes						TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

International Family Members for US Patent 9,233,117

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014287408
Australia	2014287422
Brazil	112016000335
Brazil	112016000350